BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, May 31, 2026
Home » Topics » Medical technology

Medical technology
Medical technology RSS Feed RSS

Aion Biosystems itempshield

Aion heats up with clearance for continuous temperature monitor

Aug. 30, 2023
By Annette Boyle
Aion Biosystems Inc. may be operating at a fever pitch right now, with FDA 510(k) clearance in hand for the company’s Itempshield device, which provides continuous measurement of body temperature. The company is targeting use of the quarter-sized device for patients with cancer and individuals in long-term care.
Read More
eAir pressure sensor

Singapore researcher develops an aero-elastic pressure sensor to improve accuracy

Aug. 30, 2023
Researchers at the National University of Singapore (NUS) developed an aero-elastic pressure sensor to be applied to minimally invasive surgeries, aiming to address issues caused by existing pressure sensors.
Read More

Appointments and advancements for Aug. 30, 2023

Aug. 30, 2023
New hires and promotions in the med-tech industry, including: Fractyl Health, Hioprobe, Rayzebio.
Read More

Financings for Aug. 30, 2023

Aug. 30, 2023
Med-tech firms raising money in public or private financings, including: Medx, Mercury Bio, Myomo.
Read More

In the clinic for Aug. 30, 2023

Aug. 30, 2023
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Novocure, Octave.
Read More

Other news to note for Aug. 30, 2023

Aug. 30, 2023
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Biotronik, Cobicure, Endra Life Sciences, Exact Sciences, Iridex, Nanovibronix, Polyvascular.
Read More

Regulatory actions for Aug. 30, 2023

Aug. 30, 2023
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aion Biosystems, Bionicm.
Read More
DNA double helix with sand hour glass

Biomarker brainteaser: Aging? Or just changing?

Aug. 30, 2023
By Anette Breindl
“Change is the only constant” is an ageless truth. In the search for age-related biomarkers, it is also a prosaic confounding factor.

Age-related biomarkers will be critical for the development of antiaging therapeutics. “Nobody is planning to do a life span study in humans,” Eric Verdin told the audience at the 10th Conference on Aging Research and Drug Development in Copenhagen on Monday. “Hence the need for … surrogate markers.”
Read More

Regulatory actions for Aug. 29, 2023

Aug. 29, 2023
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: ICU Medical.
Read More
India map on technology concept background

India takes steps to separate device and drug regulations

Aug. 29, 2023
By Alfred Romann
India is taking steps to separate how it regulates medical devices and pharmaceuticals, as it works to reduce its dependency on imports of devices and turn itself into a global hub for med-tech innovation and manufacturing.
Read More
Previous 1 2 … 595 596 597 598 599 600 601 602 603 … 10249 10250 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 29, 2026.
  • Floating antibody drug conjugates

    TROP2 ADCs progress into first-line for lung, breast cancers

    BioWorld
    Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
  • Illustration of antibodies and viral infection

    New evidence links autoimmunity to long COVID symptoms

    BioWorld
    Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
  • U.S. Capitol building

    BMS-Hengrui deal strikes panic in Washington

    BioWorld
    On the heels of the multibillion-dollar licensing deal between Bristol Myers Squibb Co. and Jiangsu Hengrui Pharmaceuticals Co. Ltd., Chairman John Moolenaar...
  • Medicine spilling onto map of Europe

    Initial data hint that US MFN pricing is hitting access in Europe

    BioWorld
    There are initial signs that President Donald Trump’s most-favored nation (MFN) policy may be further delaying access to new drugs in Europe, as companies hold...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing